<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="196808">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00528957</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-104-0352</org_study_id>
    <nct_id>NCT00528957</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children</brief_title>
  <official_title>A Phase III, Randomized, Open-Label Study Comparing the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate Versus Continuing Stavudine or Zidovudine in Virologically Suppressed HIV-Infected Children Taking Highly Active Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of switching to tenofovir
      disoproxil fumarate (TDF) compared to continuing stavudine or zidovudine in maintaining
      virologic suppression in HIV-1 infected children.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at Week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>This is the percentage of participants with HIV-1 RNA &lt; 400 copies/mL after 48 weeks of exposure to randomized study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 400 Copies/mL, Snapshot)</measure>
    <time_frame>48 weeks</time_frame>
    <description>This is the percentage of participants with virologic success after 48 weeks of exposure to randomized study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at Week 96</measure>
    <time_frame>96 weeks</time_frame>
    <description>This is the percentage of participants with HIV-1 RNA &lt; 400 copies/mL after 96 weeks of exposure to TDF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at Week 144</measure>
    <time_frame>144 weeks</time_frame>
    <description>This is the percentage of participants with HIV-1 RNA &lt; 400 copies/mL after 144 weeks of exposure to TDF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at 192 Weeks</measure>
    <time_frame>192 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at 240 Weeks</measure>
    <time_frame>240 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at 288 Weeks</measure>
    <time_frame>288 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at 336 Weeks</measure>
    <time_frame>336 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at 48 Weeks</measure>
    <time_frame>48 weeks</time_frame>
    <description>This is the percentage of participants with HIV-1 RNA &lt; 50 copies/mL after 48 weeks of exposure to randomized study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at 96 Weeks</measure>
    <time_frame>96 weeks</time_frame>
    <description>This is the percentage of participants with HIV-1 RNA &lt; 50 copies/mL after 96 weeks of exposure to TDF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at 144 Weeks</measure>
    <time_frame>144 weeks</time_frame>
    <description>This is the percentage of participants with HIV-1 RNA &lt; 50 copies/mL after 144 weeks of exposure to TDF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at 192 Weeks</measure>
    <time_frame>192 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at 240 Weeks</measure>
    <time_frame>240 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at 288 Weeks</measure>
    <time_frame>288 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at 336 Weeks</measure>
    <time_frame>336 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Percentage at 48 Weeks</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>This is the change from baseline in CD4 percentage after 48 weeks of exposure to randomized study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Percentage at 96 Weeks</measure>
    <time_frame>Baseline and 96 weeks</time_frame>
    <description>This is the change from baseline in CD4 percentage after 96 weeks of exposure to TDF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Percentage at 144 Weeks</measure>
    <time_frame>Baseline and 144 weeks</time_frame>
    <description>This is the change from baseline in CD4 percentage after 144 weeks of exposure to TDF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Percentage at 192 Weeks</measure>
    <time_frame>Baseline and 192 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Percentage at 240 Weeks</measure>
    <time_frame>Baseline and 240 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Percentage at 288 Weeks</measure>
    <time_frame>Baseline and 288 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Percentage at 336 Weeks</measure>
    <time_frame>Baseline and 336 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Cell Count (Cells/mm^3) at 48 Weeks</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>This is the change from baseline in CD4 cell count after 48 weeks of exposure to randomized study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Cell Count (Cells/mm^3) at 96 Weeks</measure>
    <time_frame>Baseline and 96 weeks</time_frame>
    <description>This is the change from baseline in CD4 cell count after 96 weeks of exposure to TDF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Cell Count (Cells/mm^3) at 144 Weeks</measure>
    <time_frame>Baseline and 144 weeks</time_frame>
    <description>This is the change from baseline in CD4 cell count after 144 weeks of exposure to TDF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Cell Count (Cells/mm^3) at 192 Weeks</measure>
    <time_frame>Baseline and 192 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Cell Count (Cells/mm^3) at 240 Weeks</measure>
    <time_frame>Baseline and 240 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Cell Count (Cells/mm^3) at 288 Weeks</measure>
    <time_frame>Baseline and 288 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Cell Count (Cells/mm^3) at 336 Weeks</measure>
    <time_frame>Baseline and 336 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Tenofovir DF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>stavudine or zidovudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir DF</intervention_name>
    <description>Tenofovir DF (oral powder or tablet): 300-mg tablets for participants &gt; 37 kg; 8-mg/kg oral powder (up to 300 mg) for participants &lt;= 37 kg. During the extension phase, participants whose weight increases to &gt; 37 kg may be switched from the oral powder to the tenofovir DF tablet.</description>
    <arm_group_label>Tenofovir DF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
    <description>Zidovudine as prescribed by the investigator prior to study entry.</description>
    <arm_group_label>stavudine or zidovudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stavudine</intervention_name>
    <description>Stavudine as prescribed by the investigator prior to study entry.</description>
    <arm_group_label>stavudine or zidovudine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          -  Documented laboratory diagnosis of HIV-1 infection

          -  Plasma HIV-1 RNA &lt; 400 copies/mL

          -  Currently on a stable stavudine or zidovudine -containing antiretroviral therapy
             regimen for at least 12 weeks

          -  Naive to tenofovir DF

        Inclusion Criteria for the First 96-Week Extension

          -  Completed 48 weeks of treatment in Arm 1 or Arm 2 of the study

          -  &lt;18 years of age (at the start of the extension)

          -  Participants initially randomized to Arm 2 will be given the option to replace
             stavudine or zidovudine with tenofovir DF in the 96-week extension at the
             investigator's discretion, if the investigator determines that tenofovir DF is safe
             and beneficial for the participant.

        Inclusion Criteria for the Second, Third, and Fourth 96-Week Extension

          -  Completed of treatment with study drug in the first extension phase

          -  &lt;18 years of age at the start of the extension. This inclusion criterion is not
             applicable in those regions where tenofovir DF is not commercially available for
             treatment of HIV-1 infection in adults.

        Exclusion Criteria:

          -  Participants receiving ongoing therapy with any of the following

          -  Nephrotoxic agents

          -  Systemic chemotherapeutic agents

               -  Systemic corticosteroids

               -  Interleukin 2 (IL 2) and other immunomodulating agents

               -  Investigational agents

          -  Pregnant or lactating participants

          -  Evidence of a gastrointestinal malabsorption syndrome or chronic nausea or vomiting
             which may confer an inability to receive an orally administered medication

          -  Current alcohol or substance abuse judged by the investigator to potentially
             interfere with participant compliance

          -  Malignancy other than cutaneous Kaposi's sarcoma (KS) or basal cell carcinoma.

          -  Active, serious infections (other than HIV-1 infection) requiring parenteral
             antibiotic therapy within 15 days prior to screening

          -  Prior history of significant renal disease (ie, nephrotic syndrome, renal dysgenesis,
             polycystic kidney disease, congenital nephrosis)

          -  Prior history of significant bone disease (ie, osteomalacia, chronic osteomyelitis,
             osteogenesis imperfecta, osteochondroses, multiple bone fractures)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University California Los Angeles, School of Medicine, Pediatric, Infectious Diseases</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Diagnostic and Treatment Center, Inc</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida, Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Mephis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Nino</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College London, Paediatrics Infectious Diseases</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Panama</country>
    <country>Puerto Rico</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 8, 2016</lastchanged_date>
  <firstreceived_date>January 3, 2007</firstreceived_date>
  <firstreceived_results_date>February 15, 2012</firstreceived_results_date>
  <firstreceived_results_disposition_date>June 8, 2011</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 3</keyword>
  <keyword>Randomized, Open-Label</keyword>
  <keyword>Treatment-Experienced</keyword>
  <keyword>Highly Active Antiretroviral Therapy</keyword>
  <keyword>HIV</keyword>
  <keyword>Tenofovir DF</keyword>
  <keyword>Pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Stavudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at a total of 9 study sites; 6 in the US, 1 in Panama, and 2 in the UK. The first participant was screened on 28 December 2006, and the last participant was randomized on 14 March 2008. The last participant observation (LPO) for the Week 48 was 06 April 2009. The LPO for the Week 144 analysis was 21 February 2011.</recruitment_details>
      <pre_assignment_details>Of the 127 screened, 97 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tenofovir DF</title>
          <description>Participants in this group received TDF during the randomized phase (48 weeks) and continued to receive TDF during the extension phase(s).</description>
        </group>
        <group group_id="P2">
          <title>Stavudine or Zidovudine</title>
          <description>Participants in this group received stavudine or zidovudine during the randomized phase (48 weeks) and then received TDF during the extension phase(s).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized Phase (Baseline to Week 48)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intolerability to oral powder</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>First Extension (Week 48 to Week 144)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38">Six participants completed the 48-week randomized phase and did not enroll in the first extension.</participants>
                <participants group_id="P2" count="41">Seven participants completed the 48-week randomized phase and did not enroll in the first extension.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Extension (Week 144 to Week 240)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34">One participant completed the first extension and did not enroll in the second extension.</participants>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Study is ongoing, therefore no participants have completed the study.</participants>
                <participants group_id="P2" count="0">Study is ongoing, therefore no participants have completed the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor adherence</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tenofovir DF</title>
          <description>Participants in this group received TDF during the randomized phase (48 weeks) and continued to receive TDF during the extension phase(s).</description>
        </group>
        <group group_id="B2">
          <title>Stavudine or Zidovudine</title>
          <description>Participants in this group received stavudine or zidovudine during the randomized phase (48 weeks) and then received TDF during the extension phase(s).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="97"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" spread="3.3"/>
                    <measurement group_id="B2" value="7" spread="2.6"/>
                    <measurement group_id="B3" value="7" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mestizo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Indian (Kuna)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Panama</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118" spread="19.8"/>
                    <measurement group_id="B2" value="119" spread="16.7"/>
                    <measurement group_id="B3" value="119" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.59" spread="3.680"/>
                    <measurement group_id="B2" value="16.59" spread="1.762"/>
                    <measurement group_id="B3" value="17.08" spread="2.905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.9" spread="12.03"/>
                    <measurement group_id="B2" value="24.1" spread="7.77"/>
                    <measurement group_id="B3" value="25.0" spread="10.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at Week 48</title>
        <description>This is the percentage of participants with HIV-1 RNA &lt; 400 copies/mL after 48 weeks of exposure to randomized study drug.</description>
        <time_frame>48 weeks</time_frame>
        <population>Intent-to-treat, Missing = Failure</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>Participants in this group received TDF during the randomized phase (48 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Stavudine or Zidovudine</title>
            <description>Participants in this group received stavudine or zidovudine during the randomized phase (48 weeks)</description>
          </group>
          <group group_id="O3">
            <title>All TDF</title>
            <description>All participants who received tenofovir DF in the randomized and/or extension phases</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at Week 48</title>
          <description>This is the percentage of participants with HIV-1 RNA &lt; 400 copies/mL after 48 weeks of exposure to randomized study drug.</description>
          <population>Intent-to-treat, Missing = Failure</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="69.8" upper_limit="92.5"/>
                    <measurement group_id="O2" value="91.8" lower_limit="80.4" upper_limit="97.7"/>
                    <measurement group_id="O3" value="85.4" lower_limit="76.3" upper_limit="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical hypotheses for the primary endpoint was as follows:
Null Hypothesis: tenofovir DF group is more than 15% worse than the stavudine or zidovudine group with respect to the proportion of participants maintaining HIV-1 RNA concentrations &lt; 400 copies/mL at Week 48.
Alternate Hypothesis: tenofovir DF group is no more than 15% worse than the stavudine or zidovudine group with respect to the proportion of participants maintaining HIV-1 RNA &lt; 400 copies/mL at Week 48.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>In the randomized phase, it was assumed that the respective proportions of participants maintaining HIV-1 RNA &lt; 400 copies/mL was 92% for participants switching to tenofovir DF and 90% for participants continuing stavudine or zidovudine, as estimated from previous GSI studies. The equivalence limit was set at −15% for the lower boundary of a two-sided 95% confidence interval (CI) on the difference in proportions of participants maintaining HIV-1 RNA &lt; 400 copies/mL at Week 48.</non_inferiority_desc>
            <param_type>Difference in percentages between groups</param_type>
            <param_value>-8.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.5</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
            <estimate_desc>Difference is for tenofovir DF minus stavudine or zidovudine (randomized phase)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 400 Copies/mL, Snapshot)</title>
        <description>This is the percentage of participants with virologic success after 48 weeks of exposure to randomized study drug.</description>
        <time_frame>48 weeks</time_frame>
        <population>ITT Analysis Set; only includes participants &lt; 12 years of age at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>Participants in this group received TDF during the randomized phase (48 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Stavudine or Zidovudine</title>
            <description>Participants in this group received stavudine or zidovudine during the randomized phase (48 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 400 Copies/mL, Snapshot)</title>
          <description>This is the percentage of participants with virologic success after 48 weeks of exposure to randomized study drug.</description>
          <population>ITT Analysis Set; only includes participants &lt; 12 years of age at baseline</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6"/>
                    <measurement group_id="O2" value="89.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>In the randomized phase, it was assumed that the respective proportions of participants maintaining HIV-1 RNA &lt; 400 copies/mL was 92% for subjects switching to tenofovir DF and 90% for subjects continuing stavudine or zidovudine, as estimated from previous GSI studies. The equivalence limit was set at −15% for the lower boundary of a two-sided 95% confidence interval (CI) on the difference in proportions of participants maintaining HIV-1 RNA &lt; 400 copies/mL at Week 48.</non_inferiority_desc>
            <param_type>Difference in percentages between groups</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.7</ci_lower_limit>
            <ci_upper_limit>11.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at Week 96</title>
        <description>This is the percentage of participants with HIV-1 RNA &lt; 400 copies/mL after 96 weeks of exposure to TDF.</description>
        <time_frame>96 weeks</time_frame>
        <population>Intent-to-treat, Missing = Failure. Participants who had not reached the upper limit of the analysis window (date varies depending on analysis time frame) were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>Participants in this group received TDF during the randomized phase (48 weeks) and continued to receive TDF during the extension phase(s).</description>
          </group>
          <group group_id="O2">
            <title>(Stavudine or Zidovudine)/TDF</title>
            <description>Participants in this group received stavudine or zidovudine during the randomized phase (48 weeks) and then received TDF during the extension phase(s)</description>
          </group>
          <group group_id="O3">
            <title>All TDF</title>
            <description>All participants who received tenofovir DF in the randomized and/or extension phases</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at Week 96</title>
          <description>This is the percentage of participants with HIV-1 RNA &lt; 400 copies/mL after 96 weeks of exposure to TDF.</description>
          <population>Intent-to-treat, Missing = Failure. Participants who had not reached the upper limit of the analysis window (date varies depending on analysis time frame) were excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.6" lower_limit="65.7" upper_limit="92.3"/>
                    <measurement group_id="O2" value="87.5" lower_limit="73.2" upper_limit="95.8"/>
                    <measurement group_id="O3" value="84.6" lower_limit="74.7" upper_limit="91.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at Week 144</title>
        <description>This is the percentage of participants with HIV-1 RNA &lt; 400 copies/mL after 144 weeks of exposure to TDF.</description>
        <time_frame>144 weeks</time_frame>
        <population>Intent-to-treat, Missing = Failure. Participants who had not reached the upper limit of the analysis window (date varies depending on analysis time frame) were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>Participants in this group received TDF during the randomized phase (48 weeks) and continued to receive TDF during the extension phase(s)</description>
          </group>
          <group group_id="O2">
            <title>(Stavudine or Zidovudine)/TDF</title>
            <description>Participants in this group received stavudine or zidovudine during the randomized phase (48 weeks) and then received TDF during the extension phase(s)</description>
          </group>
          <group group_id="O3">
            <title>All TDF</title>
            <description>All participants who received tenofovir DF in the randomized and/or extension phases (All TDF group)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at Week 144</title>
          <description>This is the percentage of participants with HIV-1 RNA &lt; 400 copies/mL after 144 weeks of exposure to TDF.</description>
          <population>Intent-to-treat, Missing = Failure. Participants who had not reached the upper limit of the analysis window (date varies depending on analysis time frame) were excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" lower_limit="56.9" upper_limit="86.6"/>
                    <measurement group_id="O2" value="89.7" lower_limit="72.6" upper_limit="97.8"/>
                    <measurement group_id="O3" value="80.6" lower_limit="69.1" upper_limit="89.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at 192 Weeks</title>
        <time_frame>192 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at 240 Weeks</title>
        <time_frame>240 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at 288 Weeks</title>
        <time_frame>288 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at 336 Weeks</title>
        <time_frame>336 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at 48 Weeks</title>
        <description>This is the percentage of participants with HIV-1 RNA &lt; 50 copies/mL after 48 weeks of exposure to randomized study drug.</description>
        <time_frame>48 weeks</time_frame>
        <population>Intent-to-treat, Missing = Failure</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>Participants in this group received TDF during the randomized phase (48 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Stavudine or Zidovudine</title>
            <description>Participants in this group received stavudine or zidovudine during the randomized phase (48 weeks)</description>
          </group>
          <group group_id="O3">
            <title>All TDF</title>
            <description>All participants who received tenofovir DF in the randomized and/or extension phases</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at 48 Weeks</title>
          <description>This is the percentage of participants with HIV-1 RNA &lt; 50 copies/mL after 48 weeks of exposure to randomized study drug.</description>
          <population>Intent-to-treat, Missing = Failure</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8" lower_limit="55.9" upper_limit="83.0"/>
                    <measurement group_id="O2" value="85.7" lower_limit="72.8" upper_limit="94.1"/>
                    <measurement group_id="O3" value="68.5" lower_limit="57.8" upper_limit="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at 96 Weeks</title>
        <description>This is the percentage of participants with HIV-1 RNA &lt; 50 copies/mL after 96 weeks of exposure to TDF.</description>
        <time_frame>96 weeks</time_frame>
        <population>Intent-to-treat, Missing = Failure. Participants who had not reached the upper limit of the analysis window (date varies depending on analysis time frame) were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>Participants in this group received TDF during the randomized phase (48 weeks) and continued to receive TDF during the extension phase(s).</description>
          </group>
          <group group_id="O2">
            <title>(Stavudine or Zidovudine)/TDF</title>
            <description>Participants in this group received stavudine or zidovudine during the randomized phase (48 weeks) and then received TDF during the extension phase(s).</description>
          </group>
          <group group_id="O3">
            <title>All TDF</title>
            <description>All participants who received tenofovir DF in the randomized and/or extension phases</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at 96 Weeks</title>
          <description>This is the percentage of participants with HIV-1 RNA &lt; 50 copies/mL after 96 weeks of exposure to TDF.</description>
          <population>Intent-to-treat, Missing = Failure. Participants who had not reached the upper limit of the analysis window (date varies depending on analysis time frame) were excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.3" lower_limit="59.8" upper_limit="88.6"/>
                    <measurement group_id="O2" value="70.0" lower_limit="53.5" upper_limit="83.4"/>
                    <measurement group_id="O3" value="73.1" lower_limit="61.8" upper_limit="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at 144 Weeks</title>
        <description>This is the percentage of participants with HIV-1 RNA &lt; 50 copies/mL after 144 weeks of exposure to TDF.</description>
        <time_frame>144 weeks</time_frame>
        <population>Intent-to-treat, Missing = Failure. Participants who had not reached the upper limit of the analysis window (date varies depending on analysis time frame) were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>Participants in this group received TDF during the randomized phase (48 weeks) and continued to receive TDF during the extension phase(s).</description>
          </group>
          <group group_id="O2">
            <title>(Stavudine or Zidovudine)/TDF</title>
            <description>Participants in this group received stavudine or zidovudine during the randomized phase (48 weeks) and then received TDF during the extension phase(s).</description>
          </group>
          <group group_id="O3">
            <title>All TDF</title>
            <description>All participants who received tenofovir DF in the randomized and/or extension phases</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at 144 Weeks</title>
          <description>This is the percentage of participants with HIV-1 RNA &lt; 50 copies/mL after 144 weeks of exposure to TDF.</description>
          <population>Intent-to-treat, Missing = Failure. Participants who had not reached the upper limit of the analysis window (date varies depending on analysis time frame) were excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2" lower_limit="46.0" upper_limit="78.2"/>
                    <measurement group_id="O2" value="72.4" lower_limit="52.8" upper_limit="87.3"/>
                    <measurement group_id="O3" value="67.2" lower_limit="54.6" upper_limit="78.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at 192 Weeks</title>
        <time_frame>192 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at 240 Weeks</title>
        <time_frame>240 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at 288 Weeks</title>
        <time_frame>288 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at 336 Weeks</title>
        <time_frame>336 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Percentage at 48 Weeks</title>
        <description>This is the change from baseline in CD4 percentage after 48 weeks of exposure to randomized study drug.</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <population>Intent-to-treat, Missing = Excluded</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>Participants in this group received TDF during the randomized phase (48 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Stavudine or Zidovudine</title>
            <description>Participants in this group received stavudine or zidovudine during the randomized phase (48 weeks).</description>
          </group>
          <group group_id="O3">
            <title>All TDF</title>
            <description>All participants who received tenofovir DF in the randomized and/or extension phases</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4 Percentage at 48 Weeks</title>
          <description>This is the change from baseline in CD4 percentage after 48 weeks of exposure to randomized study drug.</description>
          <population>Intent-to-treat, Missing = Excluded</population>
          <units>CD4 Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="4.49"/>
                    <measurement group_id="O2" value="1.1" spread="4.73"/>
                    <measurement group_id="O3" value="0.6" spread="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Percentage at 96 Weeks</title>
        <description>This is the change from baseline in CD4 percentage after 96 weeks of exposure to TDF.</description>
        <time_frame>Baseline and 96 weeks</time_frame>
        <population>Intent-to-treat, Missing = Excluded</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>Participants in this group received TDF during the randomized phase (48 weeks) and continued to receive TDF during the extension phase(s).</description>
          </group>
          <group group_id="O2">
            <title>(Stavudine or Zidovudine)/TDF</title>
            <description>Participants in this group received stavudine or zidovudine during the randomized phase (48 weeks) and then received TDF during the extension phase(s).</description>
          </group>
          <group group_id="O3">
            <title>All TDF</title>
            <description>All participants who received tenofovir DF in the randomized and/or extension phases</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4 Percentage at 96 Weeks</title>
          <description>This is the change from baseline in CD4 percentage after 96 weeks of exposure to TDF.</description>
          <population>Intent-to-treat, Missing = Excluded</population>
          <units>CD4 Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="4.08"/>
                    <measurement group_id="O2" value="-0.1" spread="3.60"/>
                    <measurement group_id="O3" value="0.6" spread="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Percentage at 144 Weeks</title>
        <description>This is the change from baseline in CD4 percentage after 144 weeks of exposure to TDF.</description>
        <time_frame>Baseline and 144 weeks</time_frame>
        <population>Intent-to-treat, Missing = Excluded</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>Participants in this group received TDF during the randomized phase (48 weeks) and continued to receive TDF during the extension phase(s).</description>
          </group>
          <group group_id="O2">
            <title>(Stavudine or Zidovudine)/TDF</title>
            <description>Participants in this group received stavudine or zidovudine during the randomized phase (48 weeks) and then received TDF during the extension phase(s).</description>
          </group>
          <group group_id="O3">
            <title>All TDF</title>
            <description>All participants who received tenofovir DF in the randomized and/or extension phases</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4 Percentage at 144 Weeks</title>
          <description>This is the change from baseline in CD4 percentage after 144 weeks of exposure to TDF.</description>
          <population>Intent-to-treat, Missing = Excluded</population>
          <units>CD4 Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="5.61"/>
                    <measurement group_id="O2" value="0.4" spread="3.59"/>
                    <measurement group_id="O3" value="0.6" spread="4.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Percentage at 192 Weeks</title>
        <time_frame>Baseline and 192 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Percentage at 240 Weeks</title>
        <time_frame>Baseline and 240 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Percentage at 288 Weeks</title>
        <time_frame>Baseline and 288 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Percentage at 336 Weeks</title>
        <time_frame>Baseline and 336 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Cell Count (Cells/mm^3) at 48 Weeks</title>
        <description>This is the change from baseline in CD4 cell count after 48 weeks of exposure to randomized study drug.</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <population>Intent-to-treat, Missing = Excluded</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>Participants in this group received TDF during the randomized phase (48 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Stavudine or Zidovudine</title>
            <description>Participants in this group received stavudine or zidovudine during the randomized phase (48 weeks).</description>
          </group>
          <group group_id="O3">
            <title>All TDF</title>
            <description>All participants who received tenofovir DF in the randomized and/or extension phases</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4 Cell Count (Cells/mm^3) at 48 Weeks</title>
          <description>This is the change from baseline in CD4 cell count after 48 weeks of exposure to randomized study drug.</description>
          <population>Intent-to-treat, Missing = Excluded</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-97" spread="416.4"/>
                    <measurement group_id="O2" value="-11" spread="280.2"/>
                    <measurement group_id="O3" value="2" spread="385.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Cell Count (Cells/mm^3) at 96 Weeks</title>
        <description>This is the change from baseline in CD4 cell count after 96 weeks of exposure to TDF.</description>
        <time_frame>Baseline and 96 weeks</time_frame>
        <population>Intent-to-treat, Missing = Excluded</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>Participants in this group received TDF during the randomized phase (48 weeks) and continued to receive TDF during the extension phase(s).</description>
          </group>
          <group group_id="O2">
            <title>(Stavudine or Zidovudine)/TDF</title>
            <description>Participants in this group received stavudine or zidovudine during the randomized phase (48 weeks) and then received TDF during the extension phase(s).</description>
          </group>
          <group group_id="O3">
            <title>All TDF</title>
            <description>All participants who received tenofovir DF in the randomized and/or extension phases</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4 Cell Count (Cells/mm^3) at 96 Weeks</title>
          <description>This is the change from baseline in CD4 cell count after 96 weeks of exposure to TDF.</description>
          <population>Intent-to-treat, Missing = Excluded</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-77" spread="408.3"/>
                    <measurement group_id="O2" value="-56" spread="305.6"/>
                    <measurement group_id="O3" value="-67" spread="358.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Cell Count (Cells/mm^3) at 144 Weeks</title>
        <description>This is the change from baseline in CD4 cell count after 144 weeks of exposure to TDF.</description>
        <time_frame>Baseline and 144 weeks</time_frame>
        <population>Intent-to-treat, Missing = Excluded</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>Participants in this group received TDF during the randomized phase (48 weeks) and continued to receive TDF during the extension phase(s).</description>
          </group>
          <group group_id="O2">
            <title>(Stavudine or Zidovudine)/TDF</title>
            <description>Participants in this group received stavudine or zidovudine during the randomized phase (48 weeks) and then received TDF during the extension phase(s).</description>
          </group>
          <group group_id="O3">
            <title>All TDF</title>
            <description>All participants who received tenofovir DF in the randomized and/or extension phases</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4 Cell Count (Cells/mm^3) at 144 Weeks</title>
          <description>This is the change from baseline in CD4 cell count after 144 weeks of exposure to TDF.</description>
          <population>Intent-to-treat, Missing = Excluded</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-139" spread="438.2"/>
                    <measurement group_id="O2" value="-120" spread="220.1"/>
                    <measurement group_id="O3" value="-130" spread="354.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Cell Count (Cells/mm^3) at 192 Weeks</title>
        <time_frame>Baseline and 192 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Cell Count (Cells/mm^3) at 240 Weeks</title>
        <time_frame>Baseline and 240 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Cell Count (Cells/mm^3) at 288 Weeks</title>
        <time_frame>Baseline and 288 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Cell Count (Cells/mm^3) at 336 Weeks</title>
        <time_frame>Baseline and 336 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were reported in the open-label randomized period (Weeks 0-48), and during the extension period when all participants received tenofovir DF.</time_frame>
      <desc>AEs were reported for the tenofovir DF and stavudine or zidovudine groups from baseline through Week 48 and for all participants who received tenofovir DF in the randomized and/or extension phases (All TDF group).
For the All TDF group, the median duration of follow-up was 151.9 weeks.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tenofovir DF</title>
          <description>Participants in this group received TDF during the randomized phase (48 weeks)</description>
        </group>
        <group group_id="E2">
          <title>Stavudine or Zidovudine</title>
          <description>Participants in this group received stavudine or zidovudine during the randomized phase (48 weeks)</description>
        </group>
        <group group_id="E3">
          <title>All TDF</title>
          <description>All participants who received tenofovir DF in the randomized and/or extension phases</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Abdominal Adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea Infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Tinea Versicolour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Rhinitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosures</name_or_title>
      <organization>Gilead Sciences</organization>
      <email>ClinicalTrialDisclosures@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
